Impact of Impella 5.5 Duration Support and Clinical Outcomes in Cardiogenic Shock: Evidence from a Systematic Review and Meta-Analysis of Observational Studies

March 1, 2026JHLT OpenOpen Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to evaluate the clinical outcomes of different durations of Impella 5.5 support in patients with cardiogenic shock.
Systematic review of observational studies
Search conducted across multiple databases
Inclusion of five studies with a total of 1,440 patients
Pooled risk ratios calculated using random-effects meta-analysis
Prolonged Impella support (>14 days) improved the likelihood of successful bridging to heart transplantation (RR: 1.96)
Associated with lower in-hospital mortality rate (RR: 0.67)
Lower rates of native heart recovery with prolonged support (RR: 0.70)
Higher risks of insertion-site hematoma (RR: 1.55) and infection (RR: 3.36)
No significant difference in bridging to durable LVAD (RR: 0.86)

We only have this paper's title and publication details.

Analysis compares short-term versus prolonged Impella 5.5 support effects in cardiogenic shock patients, suggesting selective benefits despite risks.

No takes yet. Share an insight, caveat, or question.

Dandamudi et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark

Share